- Home
- KF vs PRLD Comparison
KF vs PRLD Comparison
Compare KF & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KF | PRLD |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.5M | 218.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KF | PRLD |
|---|---|---|
| Price | $64.03 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 22.3K | ★ 506.5K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $21.20 | $0.75 |
| 52 Week High | $72.06 | $5.54 |
Technical Indicators
Market Signals| Indicator | KF | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 48.21 |
| Support Level | $28.52 | $1.09 |
| Resistance Level | $72.06 | $5.43 |
| Average True Range (ATR) | 2.39 | 0.52 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 48.76 | 25.88 |
Price Performance
Historical ComparisonAbout KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.